Punit Dhillon is CEO and Chairman of Nasdaq-listed biotech Skye Bioscience, entrepreneur and author. Skye’s lead candidate, nimacimab, a CB1 receptor inhibitor, is a Phase 2 stage clinical candidate in patients with obesity. Prior to Skye, Dhillon co-founded and led OncoSec Medical, raising over $200M and establishing partnerships with Merck and Genentech, and prior to that, served in several leadership roles at pharma companies. Dhillon co-founded YELL Canada, an accelerator program for high school students interested in business and entrepreneurship. He's received several awards, including the Biocom Catalyst Award and BASS Alumni Community Impact Award. He holds a BA in political science with a minor in business administration from Simon Fraser University.